{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:17:33Z","timestamp":1758709053902},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/s41409-017-0038-8","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T12:41:46Z","timestamp":1513341706000},"page":"344-346","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions"],"prefix":"10.1038","volume":"53","author":[{"given":"K","family":"Burley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DI","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"38_CR1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129:1134\u201342.","journal-title":"Blood"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1158\/0008-5472.CAN-12-1728","volume":"72","author":"G Choi","year":"2012","unstructured":"Choi G, Huang B, Pinarbasi E, Braunstein S, Horvai A, Kogan S, et al. Genetically mediated NF1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 2012;72:6425\u201334.","journal-title":"Cancer Res"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"A Fielding","year":"2007","unstructured":"Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","volume":"84","author":"G Specchia","year":"2005","unstructured":"Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84:792\u201395.","journal-title":"Ann Hematol"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding A, Schuh A, Ribera J, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.NEJM. 2017;376:836\u201347.","journal-title":"NEJM"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. NEJM. 2016;375:740\u201353.","journal-title":"NEJM"},{"key":"38_CR7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"S Maude","year":"2014","unstructured":"Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM. 2014;371:1507\u201317.","journal-title":"NEJM"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983\u201392.","journal-title":"Blood"},{"key":"38_CR9","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"D DeAngelo","year":"2007","unstructured":"DeAngelo D, Yu D, Johnson J, Stone R, Stopeck A, Gockerman J, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia Group B study 19801. Blood. 2007;109:5136\u201342.","journal-title":"Blood"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbmt.2013.04.010","volume":"19","author":"E Forcade","year":"2013","unstructured":"Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant. 2013;19:1124\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bmt.1701064","volume":"21","author":"J Passweg","year":"1998","unstructured":"Passweg J, Tiberghien P, Cahn J, Vowels M, Camitta B, Gale R, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:153\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","volume":"26","author":"R Collins Jr","year":"2000","unstructured":"Collins R Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","volume":"41","author":"A Loren","year":"2008","unstructured":"Loren A, Porter D. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41:483\u201393.","journal-title":"Bone Marrow Transplant"},{"key":"38_CR14","unstructured":"GlaxoSmithKline: Arranon\u00ae (nelarabine) injection for intravenous use (product information). Research Triangle Park, NC, USA; 2005."},{"key":"38_CR15","doi-asserted-by":"publisher","unstructured":"Kuhlen M, Bleckmann K, M\u00f6ricke A, Schrappe M, Vieth S, Escherich G et al. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. BJ Haematol. 2017; e-pub ahead of print, 2 August 2017; \n                        https:\/\/doi.org\/10.1111\/bjh.14877\n                        \n                    .","DOI":"10.1111\/bjh.14877"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0038-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-017-0038-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:59Z","timestamp":1684617059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0038-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1038\/s41409-017-0038-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,21]]}}}